|
A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma |
|
|
Employment - Ascentage Pharma; Ascentage Pharma |
Leadership - Ascentage Pharma; Ascentage Pharma |
Stock and Other Ownership Interests - Ascentage Pharma; Ascentage Pharma |
|
|
Employment - Ascentage Pharma; Guangzhou Healthquest Pharma |
Leadership - Ascentage Pharma; Guangzhou Healthquest Pharma |
Stock and Other Ownership Interests - Ascentage Pharma; Guangzhou Healthquest Pharma |